TrumpRx & Direct-to-Consumer GLP-1 Pricing

What TrumpRx actually is

TrumpRx is a federal direct-to-consumer (DTC) drug website that went live on February 5, 2026. It is the consumer-facing piece of a broader Most Favored Nation pricing initiative — a 2025 executive order pushing US prices for certain drugs toward what other wealthy countries pay — and it followed a November 2025 framework between the administration and the two companies that dominate the GLP-1 market, Eli Lilly (tirzepatide: Zepbound, Mounjaro) and Novo Nordisk (semaglutide: Wegovy, Ozempic).

The single most important thing to understand, and the part the headlines tend to blur, is this: TrumpRx does not sell you the drug. It is a navigator. You search a medication, and the site routes you to the manufacturer’s own direct-to-consumer pharmacy — primarily LillyDirect for tirzepatide and NovoCare for semaglutide — or it generates a coupon you can take to a participating retail pharmacy. The prescription, the payment, and the shipment all happen on the manufacturer’s channel. TrumpRx is the front door, not the dispensary.

That distinction matters because the manufacturer DTC programs it points to already existed before TrumpRx launched. Lilly began offering cash discounts on Zepbound through LillyDirect back in 2024; Novo Nordisk followed with NovoCare self-pay pricing in 2025. What the 2026 deal added was a coordinated set of lower “most favored nation” prices and a single government portal advertising them in one place.

Note: Because TrumpRx is a referral layer, the price you ultimately pay is set by the manufacturer program it sends you to — not by the portal. Two people searching the same drug can land on different numbers depending on brand, dose, and which introductory window is open.

The 2026 price picture

Pricing through these channels shifted repeatedly across late 2025 and into 2026, and several figures are explicitly introductory. As of mid-2026, the rough landscape for cash self-pay buyers looked like this:

• Injectable semaglutide (Wegovy, Ozempic) through NovoCare: introductory pricing has been advertised near $199/month for the first fills, stepping up to roughly $349/month for ongoing maintenance once the intro window closes.
• Injectable tirzepatide (Zepbound) through LillyDirect’s vial program: roughly $299/month for the starter dose, rising to around $399–$449/month for higher doses. The single-dose vial format runs meaningfully cheaper than the pre-filled pen for the same drug, but it’s a more hands-on format.
• Oral semaglutide (the Wegovy pill): listed as low as ~$149/month for certain doses under promotional pricing, making it one of the cheapest legitimate brand entry points.
• TrumpRx headline average: officials framed the injectable average at around $350/month, with intro doses as low as $199, and a projected glide path toward roughly $245–$250 over about two years.

When the original announcement was made in late 2025, the marquee figure was “$350 a month.” By the time the portal actually launched, competitive pressure had pushed several entry prices lower — Novo publicly cut some semaglutide self-pay pricing to $199 for early fills. The practical takeaway is that $350 is a ceiling-ish average, not a floor, and the real number depends entirely on brand, dose, and timing. Treat any single quoted figure as a snapshot that can move.

For brand-by-brand specifics — exactly what Wegovy versus Zepbound versus Ozempic cost across each payment route — the dedicated cost pages go deeper than this overview does.

The catch most coverage skips: cash-pay vs. insurance

This is the part worth slowing down on, because it’s where people get the math wrong.

The DTC discounts are cash-pay prices, and they’re measured against full list price — the four-figure “sticker” that almost nobody with insurance actually paid. So “Ozempic drops from over $1,000 to $199” is technically true and also a little misleading: most insured patients were never paying $1,000 out of pocket in the first place.

Two consequences follow:

1. Cash DTC purchases generally don’t count toward your insurance deductible or out-of-pocket maximum. If you pay $300 cash through a manufacturer channel, that money usually doesn’t move you toward the point where your plan starts covering everything for the year.
2. If you have a commercial plan that already covers GLP-1s at a modest copay, your insurance may be the cheaper route — and it builds toward your deductible besides.

So the honest framing is: the direct-to-consumer channel is a genuine win for people who are uninsured, underinsured, or whose plan flatly excludes weight-loss drugs. For someone with solid pharmacy coverage, it can quietly be the more expensive option. Running both numbers — your plan’s copay versus the cash price — before committing is the move. Our insurance coverage explainer walks through how to figure out what your specific plan does.

Who’s actually eligible

A few eligibility realities shape who benefits:

You still need a prescription. These are prescription medications. The manufacturer pharmacies require a valid script from a licensed US provider — your own clinician or, in many cases, a telehealth visit offered through the channel. Cheaper pricing changes the cost, not the requirement for a real clinical evaluation.

Government beneficiaries are typically excluded from the cash self-pay offers. People on Medicare, Medicaid, TRICARE, or VA benefits generally can’t use the manufacturer self-pay programs, even if they’d prefer to pay cash. That’s a longstanding feature of pharma self-pay coupons, not a quirk of TrumpRx.

Medicare has its own separate track. Distinct from the cash DTC channel, a Medicare pathway taking effect in mid-2026 covers injectable GLP-1s — including for weight management, a first — at a negotiated price near $245/month to the program, with a capped monthly copay (around $50) for beneficiaries who meet the eligibility tiers and aren’t receiving low-income subsidies. State Medicaid programs were also given access to the negotiated price. If you’re a Medicare or Medicaid beneficiary, that track — not the cash portal — is almost certainly your relevant route.

How this fits the wider 2026 access landscape

TrumpRx didn’t invent direct-to-consumer GLP-1 sales; it consolidated and amplified a trend that was already reshaping access:

• Manufacturer DTC pharmacies (LillyDirect, NovoCare) remain the actual engines — TrumpRx just routes to them.
• Retailers entered the cash-pay space too: in late 2025 Costco began offering semaglutide at around $499/month for cash members, and Walmart rolled out a comparable tirzepatide arrangement with Lilly. These sit above the newest manufacturer-direct floors but offer in-person pickup.
• Oral GLP-1s changed the entry price. The oral semaglutide pill arrived as a cheaper needle-free option, and a non-peptide small-molecule oral, orforglipron, broadened the field further in 2026 — adding price competition that helps push the whole category down.

Set against the compounded GLP-1 wind-down — where the shortage-era cheap compounded versions were being phased out as the official shortage resolved — the DTC channel is, in part, the legitimate, brand-name answer to “where do I get an affordable GLP-1 now that compounded supply is closing?” It’s pricier than gray-market compounded vials were, but it’s authentic, pharmacy-dispensed, FDA-approved product.

Is it the right route for you?

There’s no universal answer, but a few honest rules of thumb:

• Uninsured or excluded from coverage? The DTC channel — found via TrumpRx or by going straight to LillyDirect/NovoCare — is likely your best legitimate cash price, and worth comparing dose by dose.
• Have commercial coverage for GLP-1s? Price your plan’s copay first; the cash route may not beat it, and it won’t build your deductible.
• On Medicare or Medicaid? Look to the separate government pathway, not the cash portal.
• Watching the budget over time? Note which prices are introductory. A $199 entry that reverts to $349 after a couple of fills changes the annual math considerably.

And a general caution: you don’t have to go through TrumpRx to get these prices. Because it’s a navigator that hands you off to the manufacturer channels, you can reach the same LillyDirect or NovoCare pricing by going to those sites directly. The portal is a convenience, not a gatekeeper.

Note: Everything here reflects pricing and policy as of June 17, 2026. This is one of the fastest-moving corners of US drug policy — introductory windows expire, negotiated rates phase in, and new oral products keep entering. Confirm the current price on the manufacturer’s own channel before you decide.

The bottom line

TrumpRx is best understood as a federal storefront window, not a pharmacy. It made manufacturer direct-to-consumer GLP-1 pricing easier to find and pinned a set of “most favored nation” numbers to it, with injectable semaglutide and tirzepatide landing roughly in the $199–$350/month range in 2026 and a stated path toward lower prices over the following couple of years. The genuine value lands with people who lack good drug coverage. For the well-insured, the cash-pay nature of the channel — measured against a list price they never paid, and not counting toward their deductible — means it’s worth doing the arithmetic before assuming the headline discount is actually a discount for you.